September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Comparison of visual and anatomical outcomes of half-dose photodynamic therapy and 689 nm laser treatment (pseudo-PDT) in eyes with chronic central serous chorioretinopathy.
Author Affiliations & Notes
  • Andrea Russo
    Eye Clinic, University of Brescia, Brescia, BS, Italy
  • Anna Cancarini
    Eye Clinic, University of Brescia, Brescia, BS, Italy
  • Elena Gambicorti
    Eye Clinic, University of Brescia, Brescia, BS, Italy
  • Sarah Duse
    Eye Clinic, University of Brescia, Brescia, BS, Italy
  • Nicolò Scaroni
    Eye Clinic, University of Brescia, Brescia, BS, Italy
  • Ciro Costagliola
    Eye Clinic, University of Molise, Campobasso, Italy
  • Francesco Semeraro
    Eye Clinic, University of Brescia, Brescia, BS, Italy
  • Footnotes
    Commercial Relationships   Andrea Russo, None; Anna Cancarini, None; Elena Gambicorti, None; Sarah Duse, None; Nicolò Scaroni, None; Ciro Costagliola, None; Francesco Semeraro, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5357. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Andrea Russo, Anna Cancarini, Elena Gambicorti, Sarah Duse, Nicolò Scaroni, Ciro Costagliola, Francesco Semeraro; Comparison of visual and anatomical outcomes of half-dose photodynamic therapy and 689 nm laser treatment (pseudo-PDT) in eyes with chronic central serous chorioretinopathy.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5357.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Acute central serous chorioretinopathy (CSC) is a common disorder in middle-aged patients, characterized by serous retinal detachment in the macular region. We evaluated half-dose verteporfin photodynamic therapy (hd-PDT) versus 689 nm laser treatment in chronic CSC.

Methods : This was a pilot study of eyes with chronic CSC. A total of 20 patients were enrolled consecutively and randomized in a 1:1 ratio to receive hd-PDT (group 1) or 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds, using a spot size with a 3000 μm diameter (group 2). Best-corrected visual acuity (BCVA) and central macular thickness (CMT) findings were compared between groups.

Results : The baseline characteristics were similar, and no significant differences between the groups were found. Both groups had significant BCVA improvements (7.3 ± 1.3 vs 7.6 ± 1.5 ETRDS letters in group 1 and 2, respectively; P = 0.64), as well as CMT reductions (-102.5 ± 13.6 vs -96.1 ± 20.5 µm in group 1 and 2, respectively; P = 0.42) at 16 weeks. Measured parameters were not significantly different between groups at any time point examined. Complete photoreceptor recovery, defined as a continuous ellipsoid zone with a discernible interdigitation zone, was observed at 16 weeks in 7 and 6 patients in group 1 and 2, respectively.

Conclusions : Both hd-PDT and 689 nm laser treatment were effective in treating chronic CSC. No significant differences in visual or anatomical outcomes were observed. Additional larger studies are warranted to corroborate our results.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

OCT series demonstrating the resolution of central serous chorioretinopathy in a 43-year-old male. A: baseline; B: 3 weeks after 689 nm laser treatment; C: 6 weeks after treatment.

OCT series demonstrating the resolution of central serous chorioretinopathy in a 43-year-old male. A: baseline; B: 3 weeks after 689 nm laser treatment; C: 6 weeks after treatment.

 

OCT series depicting the reabsorption of a chronic foveal detachment in dome-shaped macula following 689 nm laser treatment, in a 51-year-old male. A: baseline; B: 4 weeks after 689 nm laser treatment.

OCT series depicting the reabsorption of a chronic foveal detachment in dome-shaped macula following 689 nm laser treatment, in a 51-year-old male. A: baseline; B: 4 weeks after 689 nm laser treatment.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×